Masks and accessories were the standout growth category for Resmed in the second quarter of its fiscal year 2026, with the company reporting a 16% increase in revenue in the United States, Canada and ...
ResMed (NYSE:RMD) is seeing growing use of wearable devices for sleep apnea pre screening, widening its reach before patients ever enter a sleep lab. Recent FDA approvals are supporting ResMed's role ...
It was once feared weight-loss drugs would crush demand for sleep apnoea products. ResMed's December quarter has shown very ...
Resmed Inc () has held its Q2 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing tools ...
7d
ResMed outlines 62%–63% gross margin target for fiscal 2026 amid double-digit growth in key segments
Q2 FY2026 earnings call recap: 11% revenue growth, margin expansion, AI innovation, and updated 62–63% guidance—read key takeaways now.
ResMed's marketing and education efforts are raising the clinical profile of sleep-disordered breathing and increasing awareness of sleep apnoea in particular. Despite signs of increasing competition ...
ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business ...
SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD) (ASX: RMD) has released the following statement from CEO Mick Farrell regarding the evolving coronavirus disease (COVID-19) outbreak: “As a global leader ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results